Home
|
Learning Center
|
中文版
Publications
站内成果搜索:
搜索
Rifaximin in treatment of patients with Irritable bowel syndrome
Rifampin Enhances the Activity of Amphotericin B against Fusarium solani Species Complex and Aspergillus flavus Species Complex Isolates from Keratitis Patients
Rifamorpholines A-E, potential antibiotics from locust-associated actinobacteria Amycolatopsis sp Hca4
Rifampin suppresses osteoclastogenesis and titanium particle-induced osteolysis via modulating RANKL signaling pathways
Rifaximin in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome
Rifampicin pre-treatment inhibits the toxicity of rotenone -induced PC12 cells by enhancing sumoylation modification of alpha-synuclein
Rifampin Use and Safety in Hospitalized Infants
Rifampicin attenuates rotenone-induced inflammation via suppressing NLRP3 inflammasome activation in microglia
Rifampicin determination in human serum and urine based on a disposable carbon paste microelectrode modified with a hollow manganese oxide@mesoporous silica oxide core-shell nanohybrid
Rifaximin for people with hepatic encephalopathy
Rifampicin-moxifloxacin interaction in tuberculosis treatment: a real-life study
Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome
Rifampicin- and Rifabutin-Resistant Listeria monocytogenes Strains Isolated from Food Products Carry Mutations in rpoB Gene
Rifaximin in Prevention of Intestinal Lesions Associated With Nonsteroidal Anti-Inflammatory Drugs: Good Idea Needing Confirmation
Rifampin-Resistant Staphylococcus aureus Bacteremia in a Patient on Chronic Rifaximin
Rifamycin SV MMX for the treatment of traveler's diarrhea
日发电计划安全校核系统开发与应用
Rifaximin and diverticular disease: Position paper of the Italian Society of Gastroenterology (SIGE)
Rifampicin as a novel tyrosinase inhibitor: Inhibitory activity and mechanism
Rifamycin action on RNA polymerase in antibiotic-tolerant Mycobacterium tuberculosis results in differentially detectable populations
Rifabutin Is Active against Mycobacterium abscessus Complex
Rifaximin in Prevention of Intestinal Lesions Associated With Nonsteroidal Anti-Inflammatory Drugs: Good Idea Needing Confirmation Reply
日法两国校长满意度比较对于中国校长职业发展的启示——基于TALIS201
日法两国休闲农业旅游发展模式的共性及对我国启示
日方档案所见中共九一八事变周年纪念活动
Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy
Rifaximin and Propranolol Combination Therapy Is More Effective than Propranolol Monotherapy for the Reduction of Portal Pressure: An Open Randomized Controlled Pilot Study
Rifaximin for the prevention of spontaneous bacterial peritonitis and hepatorenal syndrome in cirrhosis: a systematic review and meta-analysis
Rifampicin-induced injury in HepG2 cells is alleviated by TUDCA via increasing bile acid transporters expression and enhancing the Nrf2-mediated adaptive response
Rifabutin Resistance Associated with Double Mutations in rpoB Gene in Mycobacterium tuberculosis Isolates
Rifampicin Attenuated Global Cerebral Ischemia Injury via Activating the Nuclear Factor Erythroid 2-Related Factor Pathway
Rifampicin-Induced Hepatic Lipid Accumulation: Association with Up-Regulation of Peroxisome Proliferator-Activated Receptor gamma in Mouse Liver
Rifamycin Resistance in Clostridium difficile Is Generally Associated with a Low Fitness Burden
Rifaximin and midodrine improve clinical outcome in refractory ascites including renal function, weight loss, and short-term survival
Rifampicin attenuates experimental autoimmune encephalomyelitis by inhibiting pathogenic Th17 cells responses
Rifaximin Decreases the Incidence and Severity of Acute Kidney Injury and Hepatorenal Syndrome in Cirrhosis
Rifaximin antibiotic treatment for restless legs syndrome: a double-blind, placebo-controlled study
Rifabutin-based High-dose Proton-pump Inhibitor and Amoxicillin Triple Regimen as the Rescue treatment for Helicobacter pylori
Rifaximin for small intestinal bacterial overgrowth in patients without irritable bowel syndrome
Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation.
Rifampicin-monoresistant Mycobacterium tuberculosis disease among children in Cape Town, South Africa
Rifamycin inhibition of WT and Rif-resistant Mycobacterium tuberculosis and Escherichia coli RNA polymerases in vitro
Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients
Rifampin-Bonded Vascular Grafts and Postoperative Infections
Rifaximin Is Effective for the Treatment of Clostridium difficile-Associated Diarrhea: Results of an Open-Label Pilot Study
Rifaximin Treatment in Hepatic Encephalopathy
Rifaximin for Irritable Bowel Syndrome without Constipation
Rifaximin for the treatment of irritable bowel syndrome
Rifaximin: a nonsystemic rifamycin antibiotic for gastrointestinal infections
Rifampin-sirolimus-voriconazole interaction in a hematopoietic cell transplant recipient
Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis?
Rifapentine for the treatment of latent tuberculosis
Rifabutin and rifampin resistance levels and associated rpoB mutations in clinical isolates of Mycobacterium tuberculosis complex
Rifaximin modulates the colonic microbiota of patients with Crohn's disease: an in vitro approach using a continuous culture colonic model system-authors' response
Rifaximin relieved global symptoms and bloating in the irritable bowel syndrome without constipation
Rifampicin reduces the plasma concentrations and the renin-inhibiting effect of aliskiren
Rifaximin - A Non-Resorbable Antibiotic with Many Indications in Gastroenterology